NCT06760182

Clinical Trial of TQH2722 Injection in Patients With Seasonal Allergic Rhinitis

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQH2722 Injection Combined With Background Therapy in Patients With Seasonal Allergic Rhinitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 169 (actual)
• Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To evaluate TQH2722 injection in all patients receiving background treatment with mometasone furoate nasal spray (MFNS) and loratadine. The efficacy, safety and immunogenicity of the solution in patients with seasonal allergic rhinitis compared with placebo are expected to include 168 patients with confirmed seasonal allergic rhinitis (SAR) who have failed to respond to standard treatments.

Conditions

• Seasonal Allergic Rhinitis

Interventions

Type	Name	Description
DRUG	TQH2722 injection	TQH2722 injection is a humanized monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Rα).
DRUG	TQH2722 Placebo	Placebo without drug substance.

Timeline

• Start date: 2025-03-10
• Primary completion: 2025-04-30
• Completion: 2025-07-01
• First posted: 2025-01-06
• Last updated: 2025-08-12

Locations

30 sites across 1 country: China